Evidence map›Paper›PMID 40404528›Full record

ArticleEuropean urology2025

Glypican-3 as a Radiotheranostic Target for Neuroendocrine Prostate Cancer.

Woonghee Lee, Joon-Yong Chung, Kwamena E Baidoo, Divya Nambiar, Falguni Basuli, Ilsa Coleman, Martin Bakht, Chennan Li, Jinho Shin, Se Un Jeong and 6 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Woonghee LeeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Joon-Yong ChungMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Kwamena E BaidooMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Divya NambiarMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Falguni BasuliChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, Rockville, MD, USA.
Ilsa ColemanDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle WA, USA.
Martin BakhtDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Chennan LiGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Jinho ShinDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Se Un JeongDepartment of Pathology, Mokdong Hospital, Ewha Women's University, Seoul, Republic of Korea.
Yong Mee ChoDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Himisha BeltranDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle WA, USA.
Adam G SowalskyGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Peter L ChoykeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Freddy E EscorciaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Molecular mechanisms underlying lineage plasticity in prostate cancerR37CA241486 · NCI · DANA-FARBER CANCER INST · PI Himisha Beltran · 2020 to 2026
$4.1M
NCI NIH HHS P50 CA097186NCI NIH HHS R37 CA241486
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40404528
PMCPMC12954628

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.